

Dolors Colomer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1190639/dolors-colomer-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231
papers

16,461
citations

61
h-index

126
g-index

241
ext. papers

18,293
ext. citations

6.7
avg, IF

5.73
L-index

#	Paper	IF	Citations
231	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2022 , 61, 37-43	5	0
230	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 TCF-1 CD8 T cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021 ,	32.3	8
229	Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia. <i>Blood</i> , 2021 , 138, 462-462	2.2	0
228	Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. <i>British Journal of Haematology</i> , 2021 , 192, 1020-1025	4.5	0
227	EOMES is essential for antitumor activity of CD8 T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 3152-3162	10.7	4
226	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , 2021 , 35, 2635-2649	10.7	10
225	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3081-3089	4.9	6
224	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. <i>Cancers</i> , 2021 , 13,	6.6	1
223	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021 , 74, 89-95	13.4	9
222	Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". <i>Journal of Hepatology</i> , 2021 , 74, 252-254	13.4	
221	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. <i>Nature Communications</i> , 2021 , 12, 651	17.4	14
220	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 2311-2324	10.7	7
219	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , 2021 , 13,	6.6	2
218	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , 2021 ,	4.5	2
217	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2021 ,	7.8	6
216	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. <i>Blood Advances</i> , 2020 , 4, 5652-5665	7.8	16
215	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. <i>British Journal of Haematology</i> , 2020 , 191, 52-61	4.5	12

214	Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. <i>Haematologica</i> , 2020 , 105, e484	6.6	1
213	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. <i>Nature Communications</i> , 2020 , 11, 3390	17.4	8
212	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. <i>Blood</i> , 2020 , 136, 1419-1432	2.2	53
211	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. <i>Haematologica</i> , 2020 , 105, 2205-2217	6.6	21
210	TBET-expressing Th1 CD4 T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in E μ -TCL1 mice. <i>British Journal of Haematology</i> , 2020 , 189, 133-145	4.5	7
209	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 1217-1224	5.1	2
208	PI3K γ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020 , 4, 4217-4231	7.8	12
207	Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2020 , 10, 22153	4.9	2
206	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020 , 34, 100-114	10.7	17
205	Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. <i>Oncogene</i> , 2020 , 39, 1185-1197	9.2	14
204	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. <i>Haematologica</i> , 2020 , 105, 1032-1041	6.6	16
203	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2019 , 104, 778-788	6.6	15
202	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019 , 98, 2319-2328	3	3
201	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 446	12.8	12
200	Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019 , 134, 4288-4288	2.2	
199	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019 , 144, 2762-2773	7.5	8
198	Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness. <i>British Journal of Haematology</i> , 2019 , 185, 755-757	4.5	3
197	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019 , 104, 576-586	6.6	28

196	Control of chronic lymphocytic leukemia development by clonally-expanded CD8 T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , 2019 , 33, 625-637	10.7	42
195	Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4132-4147	15.9	14
194	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 2650-2650	2.2	
193	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , 2018 , 132, 4299-4299	2.2	
192	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). <i>Blood</i> , 2018 , 132, 1385-1385	2.2	
191	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2318-2326	1.9	2
190	Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 112	22.4	19
189	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017 , 96, 639-646	3	6
188	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , 2017 , 67, 501-507	13.4	37
187	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 2831-2841	12.9	88
186	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017 , 102, e360-e363	6.6	17
185	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017 , 178, 764-771	4.5	19
184	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 2059-2066	4.9	4
183	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2017 , 177, 557-561	4.5	11
182	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor- κ B mutational status. <i>Haematologica</i> , 2017 , 102, e447-e451	6.6	12
181	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 1041-1052	6.2	2
180	Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. <i>British Journal of Haematology</i> , 2017 , 177, 147-150	4.5	5
179	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , 2017 , 96, 81-85	3	15

178	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 1493-1505	12.9	28
177	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 192-201	6.7	24
176	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. <i>Clinical Cancer Research</i> , 2016 , 22, 2755-64	12.9	42
175	CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016 , 7, 5507-20	3.3	13
174	Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells. <i>Stem Cells</i> , 2016 , 34, 581-7	5.8	13
173	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 127, 2122-30	2.2	188
172	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015 , 526, 519-24	50.4	565
171	Fluorescent nucleoside derivatives as a tool for the detection of concentrative nucleoside transporter activity using confocal microscopy and flow cytometry. <i>Molecular Pharmaceutics</i> , 2015 , 12, 2158-66	5.6	8
170	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. <i>Modern Pathology</i> , 2015 , 28, 1435-47	9.8	29
169	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2015 , 62, 72-4	13.4	59
168	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 668-80	5	18
167	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015 , 6, 22734-49	3.3	49
166	Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. <i>Oncotarget</i> , 2015 , 6, 21159-72	3.3	8
165	Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. <i>Blood</i> , 2015 , 126, 3902-3902	2.2	
164	Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes. <i>Clinical Cancer Research</i> , 2014 , 20, 393-403	12.9	20
163	Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. <i>Cancer Cell</i> , 2014 , 25, 7-9	24.3	17
162	B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. <i>British Journal of Haematology</i> , 2014 , 164, 570-8	4.5	29
161	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. <i>Genome Research</i> , 2014 , 24, 212-26	9.7	143

160	Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours. <i>Journal of Pathology</i> , 2014 , 234, 423-30	9.4	48
159	Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib). <i>Clinical Cancer Research</i> , 2014 , 20, 3458-71	12.9	21
158	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014 , 123, 3790-6	2.2	82
157	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014 , 99, e231-4	6.6	27
156	4-Amino-2-aryl-amino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. <i>European Journal of Medicinal Chemistry</i> , 2014 , 86, 664-75	6.8	17
155	In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. <i>Modern Pathology</i> , 2014 , 27, 1599-611	9.8	19
154	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. <i>Haematologica</i> , 2014 , 99, 873-80	6.6	28
153	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014 , 124, 1062-9	26.8	
152	CXCR5-mediated shaping of the lymphoid follicle in chronic lymphocytic leukemia. <i>Cancer Discovery</i> , 2014 , 4, 1374-6	24.4	1
151	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. <i>Annals of Hematology</i> , 2014 , 93, 797-802	3	7
150	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. <i>Blood</i> , 2014 , 124, 4680-4680	2.2	5
149	Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. <i>Oncotarget</i> , 2014 , 5, 726-39	3.3	17
148	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. <i>Oncotarget</i> , 2014 , 5, 6788-800	3.3	31
147	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. <i>Blood</i> , 2014 , 124, 1677-1677	2.2	1
146	The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2013 , 98, 1739-47	6.6	38
145	Clonal evolution in chronic lymphocytic leukemia: analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 920-7	5	13
144	Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. <i>Clinical Cancer Research</i> , 2013 , 19, 586-97	12.9	19
143	Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. <i>Clinical Chemistry</i> , 2013 , 59, 938-48	5.5	38

142	Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies. <i>Acta Haematologica</i> , 2013 , 129, 65-71	2.7	3
141	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 18250-5	11.5	377
140	Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. <i>Autophagy</i> , 2013 , 9, 115-7	10.2	20
139	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013 , 121, 2734-8	2.2	196
138	SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. <i>Blood</i> , 2013 , 121, 2175-85	2.2	109
137	Follicular Dendritic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120. <i>Blood</i> , 2013 , 122, 3072-3072	2.2	2
136	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. <i>Blood</i> , 2013 , 122, 378-378	2.2	5
135	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. <i>Oncotarget</i> , 2013 , 4, 1931-2	3.3	9
134	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. <i>Oncotarget</i> , 2013 , 4, 1919-1932	3.3	1
133	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012 , 44, 1236-42	36.3	422
132	Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 881-9	5	51
131	NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 1064-1065	5	
130	A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012 , 156, 612-8	4.5	7
129	Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. <i>Clinical Cancer Research</i> , 2012 , 18, 5278-89	12.9	49
128	Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. <i>Cancer Research</i> , 2012 , 72, 5307-16	10.1	195
127	Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2012 , 97, 943-51	6.6	17
126	Molecular pathogenesis of mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3416-23	15.9	275
125	Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell NonBlodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 3935-3935	2.2	3

124	The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2012 , 120, 1647-1647	2.2	0
123	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2011 , 44, 47-52	36.3	752
122	The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. <i>American Journal of Pathology</i> , 2011 , 179, 2601-10	5.8	45
121	Nonhepatosplenic T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 1214-25	6.7	107
120	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011 , 96, 1470-7	6.6	48
119	The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. <i>Blood</i> , 2011 , 117, 1270-9	2.2	91
118	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. <i>Leukemia Research</i> , 2011 , 35, 1276-8	2.7	4
117	A putative "hepitype" in the ATM gene associated with chronic lymphocytic leukemia risk. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 887-95	5	5
116	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011 , 475, 101-5	50.4	1206
115	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2011 , 35, 1014-9	2.7	44
114	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2064-8	1.9	13
113	Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. <i>Clinical Cancer Research</i> , 2011 , 17, 3956-68	12.9	67
112	Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011 , 30, 1324-40	1.4	14
111	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , 2010 , 116, e111-7	2.2	120
110	In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. <i>Clinical Cancer Research</i> , 2010 , 16, 2046-54	12.9	73
109	NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2010 , 14, 275-88	6.4	37
108	Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. <i>Cancer Research</i> , 2010 , 70, 1408-18	10.1	373
107	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010 , 95, 1317-24	6.6	41

106	Stability of Conversion Factors for BCR-ABL Monitoring -Implications for the Frequency of Validation Rounds. <i>Blood</i> , 2010 , 116, 893-893	2.2	3
105	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. <i>Blood</i> , 2010 , 116, 625-625	2.2	
104	The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma. <i>Blood</i> , 2010 , 116, 3918-3918	2.2	
103	B Cell Stimulation through BCR and CD40 Modulates the Response of Chronic Lymphocytic Leukemia Cells to BAFF and APRIL.. <i>Blood</i> , 2010 , 116, 1361-1361	2.2	
102	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , 2010 , 116, 894-894	2.2	0
101	MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. <i>Cancer Research</i> , 2009 , 69, 7071-8	10.1	72
100	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009 , 94, 1555-62	6.6	299
99	p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective I κ B kinase inhibitor BMS-345541. <i>Clinical Cancer Research</i> , 2009 , 15, 2767-76	12.9	28
98	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. <i>American Journal of Hematology</i> , 2009 , 84, 102-8	7.1	94
97	Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma. <i>Histopathology</i> , 2009 , 55, 230-2	7.3	9
96	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. <i>Blood</i> , 2009 , 114, 1563-75	2.2	46
95	BAFF and APRIL in Chronic Lymphocytic Leukemia: Clinico-Biological Correlates and Prognostic Significance.. <i>Blood</i> , 2009 , 114, 1235-1235	2.2	1
94	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. <i>Blood</i> , 2009 , 114, 1113-1113	2.2	
93	Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. <i>European Urology</i> , 2008 , 54, 1363-72	10.2	34
92	Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2008 , 68, 10178-86	10.1	64
91	Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. <i>Clinical Cancer Research</i> , 2008 , 14, 6907-15	12.9	61
90	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008 , 93, 1843-51	6.6	17
89	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008 , 112, 3130-4	2.2	129

88	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008 , 93, 207-14	6.6	23
87	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008 , 93, 132-6	6.6	11
86	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. <i>Annals of Hematology</i> , 2008 , 87, 269-76	3	36
85	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 1086-97	5	26
84	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. <i>American Journal of Hematology</i> , 2007 , 82, 849-51	7.1	26
83	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. <i>Nature Reviews Cancer</i> , 2007 , 7, 750-62	31.3	387
82	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007 , 136, 590-6	4.5	63
81	Selective inhibition of I κ B kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. <i>Journal of Immunology</i> , 2007 , 178, 1923-30	5.3	75
80	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. <i>Haematologica</i> , 2007 , 92, 308-14	6.6	61
79	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. <i>Blood</i> , 2007 , 109, 4441-9	2.2	177
78	Epstein-Barr virus negative clonal plasma cell proliferations and lymphomas in peripheral T-cell lymphomas: a phenomenon with distinctive clinicopathologic features. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 1310-22	6.7	61
77	BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2007 , 110, 3464-3464	2.2	1
76	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. <i>Blood</i> , 2007 , 110, 2532-2532	2.2	
75	Molecular biology in acute leukemia. <i>Clinical and Translational Oncology</i> , 2006 , 8, 550-9	3.6	5
74	Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 166, 89-93		11
73	Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. <i>Pathology International</i> , 2006 , 56, 440-8	1.8	19
72	The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. <i>Hepatology</i> , 2006 , 44, 44-52	11.2	94
71	ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2006 , 12, 726-34	12.9	40

70	Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. <i>Clinical Cancer Research</i> , 2006 , 12, 3754-61	12.9	28
69	Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. <i>Cancer Research</i> , 2006 , 66, 6947-54	10.1	111
68	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. <i>Blood</i> , 2006 , 107, 257-64	2.2	385
67	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 4563-9	2.2	114
66	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. <i>Leukemia Research</i> , 2006 , 30, 923-34	2.7	40
65	Obatoclox (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 832-832	2.2	5
64	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. <i>Blood</i> , 2006 , 108, 2707-2707	2.2	
63	FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. <i>Blood</i> , 2006 , 108, 2348-2348	2.2	
62	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. <i>Blood</i> , 2006 , 108, 3598-3598	2.2	
61	Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. <i>Haematologica</i> , 2006 , 91, 11-6	6.6	57
60	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. <i>Haematologica</i> , 2006 , 91, 169-75	6.6	173
59	Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. <i>Haematologica</i> , 2006 , 91, 895-902	6.6	57
58	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. <i>Oncogene</i> , 2005 , 24, 7213-23	9.2	189
57	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. <i>Leukemia Research</i> , 2005 , 29, 595-7	2.7	9
56	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. <i>Nature Genetics</i> , 2005 , 37, 391-400	36.3	1492
55	Reply to Schmidt MYST3/CREBBP (MOZ/CBP) and CREBBP/MYST3(CBP/MOZ) Transcripts in AML with t(8;16)(p11;p13) <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 209-209	5	
54	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. <i>Journal of Pathology</i> , 2005 , 205, 507-13	9.4	62
53	CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. <i>Cancer Research</i> , 2005 , 65, 2199-206	10.1	80

52	Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2797-804	2.2	205
51	Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3433-8	2.2	116
50	Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , 2005 , 46, 717-22	1.9	25
49	Severe Myelodysplasia with Monosomy 7 Developing during Imatinib Treatment of Philadelphia-Positive Chronic Myeloid Leukemia: Two Cases Evolving with Different Outcome.. <i>Blood</i> , 2005 , 106, 4861-4861	2.2	
48	c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.. <i>Blood</i> , 2005 , 106, 4820-4820	2.2	
47	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. <i>Blood</i> , 2005 , 106, 3009-3009	2.2	
46	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2004 , 103, 1237-43 ²	2.2	338
45	Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: multiinstitutional laboratory trial. <i>Clinical Chemistry</i> , 2004 , 50, 1088-92	5.5	7
44	Cytotoxic effects of B lymphocytes mediated by reactive oxygen species. <i>Current Pharmaceutical Design</i> , 2004 , 10, 841-53	3.3	10
43	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. <i>Oncogene</i> , 2004 , 23, 8941-9	9.2	22
42	Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. <i>Genes Chromosomes and Cancer</i> , 2004 , 40, 140-5	5	63
41	Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. <i>American Journal of Pathology</i> , 2004 , 164, 501-10	5.8	86
40	Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature. <i>Transplantation</i> , 2004 , 77, 311-3	1.8	22
39	Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients: clinicopathologic observations and molecular analysis. <i>American Journal of Surgical Pathology</i> , 2004 , 28, 849-58	6.7	55
38	The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982-2004).. <i>Blood</i> , 2004 , 104, 5287-5287	2.2	0
37	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. <i>Blood</i> , 2004 , 104, 2054-2054	2.2	
36	Equilibrative Nucleoside Transporter-2 (ENT2) Protein Correlates with Ex-Vivo Sensitivity to Fludarabine in Chronic Lymphocytic Leukemia (CLL)-Cells.. <i>Blood</i> , 2004 , 104, 2079-2079	2.2	
35	Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 2328-34	2.2	93

34	Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. <i>Blood</i> , 2003 , 101, 3674-80	2.2	121
33	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. <i>Experimental Hematology</i> , 2003 , 31, 204-10	3.1	35
32	Mechanism of action and resistance to monoclonal antibody therapy. <i>Seminars in Oncology</i> , 2003 , 30, 424-33	5.5	71
31	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003 , 141, 114-9		14
30	High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003 , 147, 36-43		25
29	Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies 2003 , 56, 8-15		24
28	ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2003 , 348, 1764-75	59.2	1093
27	Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1472-9	2.2	80
26	Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44, 71-6	1.9	33
25	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003 , 101, 78-84	2.2	322
24	Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. <i>Circulation</i> , 2003 , 107, 2428-34	16.7	138
23	CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. <i>Experimental Hematology</i> , 2002 , 30, 824-30	3.1	21
22	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 119, 976-84	4.5	146
21	Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4032-9	2.2	49
20	Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 99, 1873-4	2.2	29
19	Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. <i>Blood</i> , 2002 , 99, 2969-76	2.2	123
18	CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. <i>Blood</i> , 2002 , 100, 4602-8	2.2	61
17	Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1810-6	2.2	102

16	Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). <i>American Journal of Pathology</i> , 2002 , 161, 957-68	5.8	75
15	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. <i>Blood</i> , 2001 , 98, 2771-7	2.2	175
14	Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3. <i>American Journal of Clinical Pathology</i> , 2000 , 114, 786-92	1.9	25
13	In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 2836-2843	2.2	153
12	Multiple forms of protein kinase CK2 present in leukemic cells: In vitro study of its origin by proteolysis. <i>Molecular and Cellular Biochemistry</i> , 1999 , 191, 229-234	4.2	8
11	β-thalassaemia due to a single codon deletion in the β1-globin gene. Computational structural analysis of the new β-chain variant. <i>Human Mutation</i> , 1998 , 11, 412-412	4.7	16
10	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 1998 , 100, 142-6	4.5	72
9	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 1998 , 92, 1406-1414	2.2	159
8	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 1998 , 92, 1406-1414	2.2	1
7	Involvement of CED-3/ICE Proteases in the Apoptosis of B-Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 1997 , 89, 3378-3384	2.2	85
6	First description of a frameshift mutation in the alpha1-globin gene associated with alpha-thalassaemia. <i>British Journal of Haematology</i> , 1997 , 98, 47-50	4.5	12
5	Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. <i>Human Mutation</i> , 1996 , 8, 311-8	4.7	13
4	Surface adenosine deaminase. A novel B-cell marker in chronic lymphocytic leukemia. <i>Human Immunology</i> , 1995 , 42, 265-73	2.3	15
3	Chronic nonspherocytic hemolytic anemia (CNSHA) and glucose 6 phosphate dehydrogenase (G6PD) deficiency in a patient with familial amyloidotic polyneuropathy (FAP). Molecular study of a new variant (G6PD Clinic) with markedly acidic pH optimum. <i>Human Genetics</i> , 1989 , 81, 161-4	6.3	8
2	Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 1988 , 27, 157-62	7.1	11
1	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation		1